Ert Pompe denied as non-formulary by Humana?

Humana's specific coverage criteria for ert pompe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Pompe Disease ERT as Non-Formulary — and Why a Medical Exception Usually Applies

A non-formulary denial means the specific ERT product prescribed for the patient's Pompe disease is not listed on Humana's preferred drug list for the applicable benefit tier. For common conditions with many competing agents, a formulary exclusion may be manageable by switching products. For Pompe disease, the FDA-approved treatment options are limited, and the prescriber may have a documented clinical reason — infusion tolerability, prior product failure, or disease-subtype considerations — for selecting the specific product requested rather than an alternative.

Humana, like all plans subject to ACA and state insurance regulations, must maintain a formulary exception process. A non-formulary exception can be granted when the formulary alternative is clinically inappropriate for that patient or when no formulary alternative exists for the condition.

## Federal Appeal Rights

ACA Section 2719 requires internal and external review for adverse benefit determinations on non-grandfathered plans, including non-formulary denials when no adequate alternative exists. ERISA Section 503 applies to self-funded employer plans. External review must generally be requested within four months of the final internal adverse determination. Expedited review is available when the standard timeline would jeopardize health.

## What to Gather

• Formulary exception request and denial — confirm in writing which formulary alternatives Humana claims exist and why the prescriber has not selected them.
• Prescriber clinical justification — the physician's explanation, grounded in the patient's chart, of why the requested product is appropriate and why any listed formulary alternative is not clinically equivalent for this patient.
• Diagnosis and treatment history — documentation of the Pompe diagnosis and any prior ERT experience, including tolerability issues or clinical response records.
• Humana formulary exception criteria — obtain the current formulary exception policy and identify what the patient must demonstrate to qualify.
• FDA label for the requested product — confirms it is FDA-approved for Pompe disease, which is relevant if Humana's exception criteria reference approved indications.

## Criteria-Mapping Structure

Address each formulary exception criterion from Humana's policy. Key arguments typically include: (1) no therapeutically equivalent formulary alternative exists for this indication; or (2) a formulary alternative was tried and resulted in inadequate response or intolerance; or (3) the non-formulary product is the only FDA-approved option for a specific disease variant. Map each argument to a chart fact or prescriber attestation.

## Process and Timeline

1. File a formal formulary exception request with the prescriber's clinical justification before or alongside the appeal — many plans treat these as the same process. 2. Submit the written internal appeal within the plan's deadline, including all documentation. 3. If denied, file for external review within four months of the final internal determination. 4. If the patient is currently stable on the requested product from samples or prior coverage, document current clinical status to support urgency.